[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514745":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":33,"locations":44,"responsibleParty":65,"collaborators":69,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":22,"enrollmentInfo":81,"targetDuration":22,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":22,"overallStatus":47,"whyStopped":22,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Università Vita-Salute San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A","EXPERIMENTAL","* Candidates to surgery as first treatment regardless of cN\n* ER+ Her2 negative BC with ki67\\>10%",[13,14,15],"Drug: FES","Procedure: PET\u002FMRI A","Genetic: Translational analysis",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","FES","16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET\u002FMRI exam",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"PROCEDURE","PET\u002FMRI A","An additional FES PET\u002FMRI will be performed before surgery.",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":22},"GENETIC","Translational analysis","Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.",[9],[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Rosa Di Micco, MD","CONTACT","+39022643","4565","dimicco.rosa@hsr.it",{"name":41,"role":36,"phone":37,"phoneExt":42,"email":43},"Nicole Rotmensz, MSc","5650","rotmensz.nicole@hsr.it",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"IRCCS Ospedale San Raffaele","RECRUITING","Milan","MI","20132","Italy","IT",{"type":54,"coordinates":55},"Point",[56,57],12.59836,42.78235,{"lat":57,"lon":56},[60,63],{"name":61,"role":36,"phone":62,"phoneExt":22,"email":39},"Rosa Di Micco, MD, PhD","+39 26434565",{"name":41,"role":36,"phone":64,"phoneExt":22,"email":43},"+390226435650",{"type":66,"investigatorFullName":35,"investigatorTitle":67,"investigatorAffiliation":68,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Principal Investigator","IRCCS San Raffaele",[70],{"name":68,"class":6},"100514745","phase-2-18f-fes-petmri-for-tailoring-treatment-of-luminal-a-and-lobular-breast-cancer-100514745",false,"NCT05982496","18F FES-PET\u002FMRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer","18F-FES PET\u002FMRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer: a Phase II Prospective Cohort Study Evaluating the Performance of FES PET\u002FMRI in Axillary Staging Compared With Axillary Surgery","FESTA","Inclusion Criteria:\n\n* Female patients, age\\>= 18 yrs, diagnosed with primary or advanced breast cancer\n* LumA or ER-positive Lobular subtypes\n\n  * candidates to surgery as first treatment regardless of cN\n  * ER-positive Her2 negative BC with ki67\\>10%\n\nExclusion Criteria:\n\n* ER-negative tumors\n* Pregnancy;\n* Contraindication to PET;\n* Contraindication to MRI;\n* Claustrophobia;\n* Allergy to the MR contrast agent;\n* Severe renal insufficiency","FEMALE","18 Years",{"count":82,"type":83},119,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","Study hypothesis is that combining the advantages of hybrid PET\u002FMRI and the high sensitivity\u002Fspecificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the investigators could obtain a reliable, non-invasive, operator-independent, one-stage imaging method for staging LumA and ER-positive Lobular tumours.",[89,90,91,92,93],"Breast Cancer Female","Lobular Breast Carcinoma","PET\u002FMRI","Axillary Lymphadenopathy","Luminal A Breast Cancer","2026-06-09",{"date":96,"type":97},"2026-06-12","ACTUAL",{"date":94,"type":97},{"date":100,"type":83},"2029-12-01",{"name":5,"class":6},1]